Thanks for the clarification. I found reference to a “weakly informative” prior on a website not attached to the online version of the paper. Although I understood the “Hail Mary” impulse, in the early days of the pandemic, to find an already-approved drug that might work against COVID, I would have eaten my hat if any of them had panned out. I guess that means that my “prior” would have been very skeptical…
1 Like
A fair comment. Drug repurposing benefits from good safety profiles but has a mechanism of action challenge.
1 Like
Would these “Statistical Analysis Plan” and “Study Protocol and Statistical Analysis Plan” documents help for starters?
- https://www.clinicaltrials.gov/study/NCT05890586#more-information might be the “main trial SAP” referenced in
- https://www.clinicaltrials.gov/study/NCT05736861#more-information with section “10.6.2. Statistical modeling” starting p 42 and
- https://www.clinicaltrials.gov/study/NCT05894538#more-information with section “10. Statistical Considerations” starting p 44
(am curating a tool for using clinical trial register data and documents https://rfhb.github.io/ctrdata/#documents-example)
1 Like